273PMALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas

Abstract Background The nuclear factor-κB (NF-κB) pathway has been considered an essential and tightly regulated signaling cascade that mediates the development, activation, and survival of lymphocytes for regulated immune responses. Moreover, many of the oncogenic mediators involved in the pathology of lymphoma are regulated by NF-κB. Abnormal NF-κB activation occurs during many pathological conditions. A20 (intracellular ubiquitin-editing protein) is a negative feedback regulator of NF-κB signaling. A20 was identified as a MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) substrate, and MALT1 can cleave A20 to impair its NF-κB inhibitory function. Methods This study was carried out on 100 subjects classified into the following groups: Group I: included 80 patients with Non-Hodgkin Lymphoma (NHL). Group II: Included 20 ages and sex matched healthy individuals as a control group. All participants were subjected to full history taking and clinical examination. All NHL cases were subjected to abdominal ultrasound & CT-scan for abdomen and metastatic work up: chest x-ray and bone scan. Blood sample were taken for CBC, ESR, Serum LDH and β2 microglobulin (β2M) levels and detection of MALT1, A20 and NF-κB genes expression in cDNA samples extracted from RNA samples by reverse transcription by using real time PCR using SYBR Green technique. Results There was significant statistical increased expression of MALT1 and NF-κB and significant statistical decreased expression of A20 in NHL cases when compared with control. In NHL patients there was significant statistical decreased expression of MALT1, A20 and NF-κBin (HCV +ve) NHL cases when compared with controls and there was significant statistical increased expression of MALT1 and NF-κBand significant statistical decreased expression of A20 in (HCV-ve) NHL cases when compared with controls. Conclusions MALT1- A20 and NF-κB have specific expression pattern in patients with Non Hodgkin Lymphomas. Legal entity responsible for the study Menoufia university. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.